Trial Profile
Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib: GIST Regorafenib Continuous Dosing
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 05 Jun 2018 Results (n=25) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Feb 2018 Status changed from recruiting to completed.
- 30 Dec 2016 Status changed from not yet recruiting to recruiting.